Glycyrrhizic acid, a major active component of licorice root (Glycyrrhiza glabra), has been studied for its hepatoprotective effects, particularly in the context of chronic liver diseases such as cirrhosis. Its use in supporting or treating cirrhosis is supported by both traditional medicine (notably in East Asia) and a growing body of scientific research, though the evidence is not considered definitive or at the highest level.

Scientifically, glycyrrhizic acid is believed to exert anti-inflammatory, antiviral, and antioxidant effects, which may help mitigate liver damage. Clinical studies—primarily from Japan and China—have evaluated preparations like Stronger Neo-Minophagen C (SNMC), which contains glycyrrhizin, in patients with chronic hepatitis and cirrhosis. Some randomized controlled trials and observational studies suggest that intravenous glycyrrhizin can reduce liver enzyme levels (ALT, AST), improve histological liver features, and possibly slow progression to cirrhosis, particularly in hepatitis B and C patients. Meta-analyses indicate modest benefits, but the overall quality of evidence is moderate, with methodological limitations and a lack of large, high-quality trials.

Despite some promising results, glycyrrhizic acid is not a primary or standalone therapy for cirrhosis and is generally considered as adjunctive support. Potential side effects (e.g., pseudoaldosteronism, hypertension, hypokalemia) limit its use. Thus, while scientific rationale and some clinical evidence exist, further well-designed studies are needed to establish efficacy and safety.